Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Laxatives monograph clarification

This article was originally published in The Tan Sheet

Executive Summary

CHPA asks FDA to accept the statement of identity "fiber laxative" as well as "the indication 'Fiber therapy for relief of occasional constipation' [which may be followed by '(irregularity)']" in a Jan. 20 letter. The trade group also requests clarification on whether "'fiber laxative' may be used as an alternative to 'bulk-forming laxative.'" CHPA's request comes after the October 2003 reopening of the administrative record for OTC laxatives (1"The Tan Sheet" Oct. 27, 2003, In Brief)...

You may also be interested in...



Laxative record open

FDA is reopening the administrative record for OTC laxative products until Jan. 20, 2004, agency announces in Oct. 22 1Federal Register. Agency explains it "has received new data and information submitted to the rulemaking for OTC laxative drug products after the administrative record closed on the various dates" since the 1985 tentative final monograph. Separately, comments on the agency's proposal to reclassify granular psyllium as Category II (not generally recognized as safe and effective) from Category I (generally recognized as safe and effective) are due Nov. 3, FDA says (2"The Tan Sheet" Aug. 11, 2003, p. 10)...

GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health

Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS096402

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel